Jamp Telmisartan-hct: Affected Lots May Contain Higher Dosage Than The Labelled Dose

JAMP Telmisartan-HCT tablets from certain lots contain a higher amount of active ingredient than what is printed on the label. This is a quality issue with the product. The affected lots were distributed across Canada.

Product

JAMP TELMISARTAN-HCT

Reason

Product quality

Classification

Class I

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2024-01-24

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/b354650f-8652-48e0-a798-8f7404592019